Roivant ends namilumab program, Bio-Thera partners on golimumab biosimilar, Caliway advances fat treatment, Orca Bio's T cell success, funding for Alterity & Ascentage ...

Alterity Therapeutics Limited (market cap: $40 million), a pharmaceutical company specializing in the development of therapeutic drugs, has secured A$40 million in funding to advance the development ...

Auddia reported acceleration of faidr 30-day retention to over 20% in October and finished the year with each month in Q4 over 20%. January retention continued to build to just below 25% and February ...

Alterity Therapeutics (ATHE) has received binding commitments for a capital raising of A$40M via a two tranche placement of fully paid ordinary ...

Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, ...

A mixed US jobs report and Trump’s announcement of new 25 per cent tariffs on aluminium and steel imports sent Australian ...

Ansell has moved to expand its manufacturing presence beyond China, to countries including India and Sri Lanka.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

MST Financial is managing the raise and has split it into two tranches. Shares were placed in a trading halt on Thursday.

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop.

CD&R has named Sam Camens as managing director. In this role, Camens will drive CD&R’s health and welfare strategy. Previously, he was managing director of insurance and benefits at Onex. He is the ...

CD&R (or the "Firm") announced today the appointment of Sam Camens as Managing Director. Sam will drive CD&R's health and welfare strategy, including supporting related diligence and investment ...